Cecilia Lindestam Arlehamn and co-workers have developed a novel peptide pool that distinguishes active tuberculosis from latent infection.

TB antigens in active vs latent infection

In their effort to help design new diagnostics and vaccines for tuberculosis (TB), Cecilia Lindestam Arlehamn and her co-workers performed a proteome-wide screening of TB derived peptides in patients with active TB vs patients with latent infection using an <a href="/products/flex/X-03A01B-1">IFNγ and IL-17 Fluorospot</a> assay and <a href="/products/iris">Mabtech IRIS</a>.&nbsp;

 
The comparison revealed that patients with active TB recognize different epitopes than otherwise healthy latent infected patients. With this information, the research group developed a peptide pool consisting of epitopes exclusively recognized by participants with active TB, allowing distinguishing patients with active disease from latent infections.

 
A peptide pool like this will be important for measuring correlates of protection in vaccine development, as well as a great possible tool for novel diagnostic assays. 
&nbsp;

Reference:

<a href="https://pubmed.ncbi.nlm.nih.gov/37090558/">Panda et al.,&nbsp;Identification of differentially recognized T cell epitopes in the spectrum of&nbsp;Mtb&nbsp;infection. Preprint. 2023</a>

Mabtech products used:

<ul>
	<li><a href="/products/flex/X-03A01B-1">FluoroSpot Flex: Human IL-17A/IFN-γ</a></li>
	<li><a href="/products/iris">Mabtech IRIS</a></li>
</ul>

TB antigens in active vs latent infection

Explore similar topics